Triple threat: new combo aims to tackle breast cancer brain metastases

NCT ID NCT04711824

Ongoing Disease control Sponsor: Colette Shen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a three-part approach for people with breast cancer that has spread to the brain. First, they receive focused radiation (stereotactic radiosurgery) along with a drug called olaparib, which may make cancer cells more sensitive to radiation. After that, they get an immunotherapy drug (durvalumab) plus standard chemotherapy. The goal is to see if this combination is safe and helps control brain tumors. The trial is currently recruiting 41 participants with triple-negative or BRCA-mutated breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olaparib (Lynparza) and durvalumab (Imfinzi)
What this could lead to: If it works, this could point toward a new treatment option for people with breast cancer that has spread to the brain, potentially improving control of brain tumors.
What could go wrong: This is an early-phase trial with only 41 participants, so results may not apply to everyone. The combination of drugs and radiation may cause side effects, and it is not yet known if it works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast neoplasm hereditary breast carcinoma metastatic malignant neoplasm in the brain triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES, ADULT BREAST CANCER

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Duke Cancer Institute

Durham, North Carolina, 27710, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, 46202, United States
Memorial Healthcare System

Hollywood, Florida, 33028, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27899, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.